Abivax S.A.
ABVX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €10,792 | €4,621 | €4,583 | €37 |
| % Growth | 133.5% | 0.8% | 12,286.5% | – |
| Cost of Goods Sold | €0 | €0 | €71 | €156 |
| Gross Profit | €10,792 | €4,493 | €4,512 | -€119 |
| % Margin | 100% | 97.2% | 98.5% | -321.6% |
| R&D Expenses | €146,532 | €103,176 | €48,725 | €47,202 |
| G&A Expenses | €32,946 | €28,112 | €7,493 | €5,579 |
| SG&A Expenses | €38,900 | €28,821 | €7,493 | €5,579 |
| Sales & Mktg Exp. | €5,954 | €709 | €0 | €0 |
| Other Operating Expenses | -€1,100 | -€47 | €52 | -€80 |
| Operating Expenses | €184,332 | €131,950 | €56,575 | €52,031 |
| Operating Income | -€185,432 | -€127,376 | -€64,836 | -€52,187 |
| % Margin | -1,718.2% | -2,756.5% | -1,414.7% | -141,045.9% |
| Other Income/Exp. Net | €2,539 | -€24,857 | -€380 | €6,626 |
| Pre-Tax Income | -€182,893 | -€152,233 | -€65,216 | -€45,561 |
| Tax Expense | -€6,651 | -€4,493 | -€4,476 | -€4,204 |
| Net Income | -€176,242 | -€147,740 | -€60,740 | -€42,452 |
| % Margin | -1,633.1% | -3,197.1% | -1,325.3% | -114,735.1% |
| EPS | -2.8 | -3.43 | -3.18 | -2.75 |
| % Growth | 18.4% | -7.9% | -15.6% | – |
| EPS Diluted | -2.8 | -3.43 | -3.18 | -2.75 |
| Weighted Avg Shares Out | 63,046 | 43,066 | 19,092 | 15,456 |
| Weighted Avg Shares Out Dil | 63,046 | 43,066 | 19,092 | 15,456 |
| Supplemental Information | – | – | – | – |
| Interest Income | €8,246 | €1,118 | €128 | €84 |
| Interest Expense | €14,111 | €13,826 | €7,022 | €3,558 |
| Depreciation & Amortization | €1,100 | €707 | €485 | €156 |
| EBITDA | -€167,682 | -€133,207 | -€53,315 | -€42,195 |
| % Margin | -1,553.8% | -2,882.6% | -1,163.3% | -114,040.5% |